BRIEF-IBio Initiates Non-Human Primate Study Of First-In-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention In Weight Regain After GLP-1 Treatment

Reuters
Yesterday
BRIEF-IBio Initiates Non-Human Primate Study Of First-In-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention In Weight Regain After GLP-1 Treatment

June 16 (Reuters) - iBio Inc IBIO.O:

  • IBIO INITIATES NON-HUMAN PRIMATE STUDY OF FIRST-IN-CLASS ACTIVIN E ANTIBODY FOLLOWING POSITIVE PRECLINICAL DATA DEMONSTRATING PREVENTION IN WEIGHT REGAIN AFTER GLP-1 TREATMENT

  • IBIO INC - IBIO-610 DRIVES 8.9% BODY WEIGHT LOSS IN MICE

  • IBIO INC - PRECLINICAL RESULTS SHOW 26% FAT REDUCTION WITH IBIO-610

  • IBIO INC - IBIO-610 PREVENTS WEIGHT REGAIN IN MICE AFTER GLP-1 THERAPY

Source text: ID:nGNXwP591

Further company coverage: IBIO.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10